news roundup
Accelerated Enrollment Solutions, a business unit of PPD, has acquired the clinical research site business of Bioclinica, which expands the AES global footprint across five continents, 20 countries, and over 180 research sites.
| advertisement
Launching Medical Devices in the Japanese Market
- How to navigate regulatory and reimbursement approval
Thursday, October 31, 2019 at 11am EDT
 Register Now
|
According to the latest analysis from Tufts CSDD, oncology drugs account for 27% of all new drug approvals in the United States since 2010, an increase from the 4% share in the 1980s. Other highlights include clinical development time for cancer drug approvals during 1999-2018 was 9% longer compared to non-cancer drugs and regulatory approval phase time for cancer approvals in the same time frame was 48% shorter on average vs. non-cancer approvals.
| advertisement
Begin with the End in Mind: The Strategic Benefit of Coordinating Site Budgeting, Contracting, & Payments
Wednesday, October 2, 2019 at 11am EDT
 Register Now |
Advarra, a provider of IRB, IBC, and research quality and compliance consulting services, will acquire Forte and its integrated suite of solutions for CTMS, CDM and research administration.
| advertisement
Successful Early Phase Drug Development of mAb Drugs
Europe: Thursday, September 26, 2019 at 3pm BST | 4pm CEST
North America: Thursday, October 3, 2019 at 11am EDT | 10am CDT | 8am PDT
 Register Now |
Articles
Over the last 15 years, the addition of novel therapies for prostate cancer have made a significant positive impact for patients. Essentially all the agents detailed in this article have demonstrated an improvement in overall survival, progression free survival, or both. Also included are promising areas for novel therapeutics such as immunotherapy and agents that target the prostate-specific membrane antigen.
|
|
